果糖二磷酸醛缩酶A在肺癌中的研究进展

doi:10.3760/cma.j.cn371439-20240727-00040

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (4): 242-245.doi: 10.3760/cma.j.cn371439-20240727-00040

果糖二磷酸醛缩酶A在肺癌中的研究进展

芦兵, 熊思玉, 蒋汶宏, 俞婷婷()

新疆医科大学第三临床医学院（肿瘤医院）肺内科，乌鲁木齐 830011

收稿日期:2024-07-27 修回日期:2025-03-05 出版日期:2025-04-08 发布日期:2025-04-21
通讯作者: 俞婷婷，Email：13579910597@163.com
基金资助:
新疆维吾尔自治区自然科学基金(2022D01C522)

Progress in the study of fructose-bisphosphate aldolase A in lung cancer

Lu Bing, Xiong Siyu, Jiang Wenhong, Yu Tingting()

Department of Pulmonary Medicine，Third Clinical Medical College （Cancer Hospital） of Xinjiang Medical University，Urumqi 830011，China

Received:2024-07-27 Revised:2025-03-05 Online:2025-04-08 Published:2025-04-21
Supported by:
Xinjiang Uygur Autonomous Region Natural Science Foundation(2022D01C522)

摘要/Abstract

摘要：

葡萄糖代谢重编程过程中的多种代谢酶及信号分子参与肺癌的发生发展，研究这些代谢酶及信号分子是肺癌临床诊疗的热点和方向之一。果糖二磷酸醛缩酶A（ALDOA）是葡萄糖代谢重编程中一个重要的催化酶，其异常表达与肺癌发生发展存在错综复杂的联系，系统探讨ALDOA在肺癌代谢中的作用，可为预测肺癌转移、预后以及耐药后的治疗提供新思路。

关键词: 肺肿瘤, 果糖-二磷酸醛缩酶, 预后

Abstract:

Various metabolic enzymes and signaling molecules in the reprogramming process of glucose metabolism are involved in the occurrence and development of lung cancer. The study of these metabolic enzymes and signaling molecules is one of the hot spots and directions in the clinical diagnosis and treatment of lung cancer. Fructose-bisphosphate aldolase A （ALDOA） is an important catalytic enzyme in the reprogramming of glucose metabolism，and the abnormal expression of ALDOA is intricately related to the occurrence and development of lung cancer. Systematically exploring of the role of ALDOA in lung cancer metabolism may provide new ideas for predicting the metastasis，prognosis，and treatment after drug resistance of lung cancer.

Key words: Lung neoplasms, Fructose-bisphosphate aldolase, Prognosis

芦兵, 熊思玉, 蒋汶宏, 俞婷婷. 果糖二磷酸醛缩酶A在肺癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(4): 242-245.

Lu Bing, Xiong Siyu, Jiang Wenhong, Yu Tingting. Progress in the study of fructose-bisphosphate aldolase A in lung cancer[J]. Journal of International Oncology, 2025, 52(4): 242-245.

参考文献 29

[1]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
[2]	Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X.
[3]	Lebrett MB, Crosbie EJ, Smith MJ, et al. Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors[J]. J Med Genet, 2021, 58(4): 217-226. DOI: 10.1136/jmedgenet-2020-107399. pmid: 33514608
[4]	罗毅君, 姚伟荣, 王晓莉. EGFR突变非小细胞肺癌脑转移靶向治疗进展[J]. 国际肿瘤学杂志, 2024, 51(11): 717-722. DOI: 10.3760/cma.j.cn371439-20240318-00121.
[5]	Tang Y, Yang X, Feng K, et al. High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma[J]. J Gastrointest Oncol, 2021, 12(1): 174-183. DOI: 10.21037/jgo-20-534. pmid: 33708434
[6]	Saito Y, Takasawa A, Takasawa K, et al. Aldolase a promotes epithelial-mesenchymal transition to increase malignant potentials of cervical adenocarcinoma[J]. Cancer Sci, 2020, 111(8): 3071-3081. DOI: 10.1111/cas.14524.
[7]	周淑萍, 盛晓曼. PKM2和ALDOA在胃癌中的表达与病理特征的相关性[J]. 安徽理工大学学报(自然科学版), 2023, 43(4): 103-108. DOI: 10.3969/j.issn.1672-1098.2023.04.015.
[8]	Yao DC, Tolan DR, Murray MF, et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr)[J]. Blood, 2004, 103(6): 2401-2403. DOI: 10.1182/blood-2003-09-3160. pmid: 14615364
[9]	Jia J, Huang W, Schörken U, et al. Crystal structure of transaldolase B from Escherichia coli suggests a circular permutation of the α/β barrel within the class Ⅰ aldolase family[J]. Structure, 1996, 4(6): 715-724. DOI: 10.1016/s0969-2126(96)00077-9. pmid: 8805555
[10]	Zhang F, Lin JD, Zuo XY, et al. Elevated transcriptional levels of aldolase A (ALDOA) associates with cell cycle-related genes in patients with NSCLC and several solid tumors[J]. BioData Min, 2017, 10: 6. DOI: 10.1186/s13040-016-0122-4. pmid: 28191039
[11]	Chang YC, Chan YC, Chang WM, et al. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression[J]. Cancer Lett, 2017, 403: 28-36. DOI: 10.1016/j.canlet.2017.06.001.
[12]	Fu H, Gao H, Qi X, et al. Aldolase a promotes proliferation and G₁/S transition via the EGFR/MAPK pathway in non-small cell lung cancer[J]. Cancer Commun (Lond), 2018, 38(1): 18. DOI: 10.1186/s40880-018-0290-3.
[13]	姜玉玲. ALDOA对肺癌细胞凋亡的影响及作用机制的初步探究[D]. 大连: 大连医科大学, 2016. DOI: 10.26994/d.cnki.gdlyu.2016.000032.
[14]	Gizak A, Wiśniewski J, Heron P, et al. Targeting a moonlighting function of aldolase induces apoptosis in cancer cells[J]. Cell Death Dis, 2019, 10(10): 712. DOI: 10.1038/s41419-019-1968-4.
[15]	Tian W, Wan X, Tian L, et al. New molecular insights into ferroptosis in lung adenocarcinoma progression and pharmacological compounds for targeted therapy[J]. J Gene Med, 2024, 26(1): e3579. DOI: 10.1002/jgm.3579.
[16]	PLOS ONE Editors. Expression of concern: fructose-bisphosphate aldolase a is a potential metastasis-associated marker of lung squamous cell carcinoma and promotes lung cell tumorigenesis and migration[J]. PLoS One, 2023, 18(4): e0285076. DOI: 10.1371/journal.pone.0285076.
[17]	Chang YC, Chiou J, Yang YF, et al. Therapeutic targeting of aldolase a interactions inhibits lung cancer metastasis and prolongs survival[J]. Cancer Res, 2019, 79(18): 4754-4766. DOI: 10.1158/0008-5472.CAN-18-4080.
[18]	Feng S, Liu H, Du P, et al. Long non-coding RNA AC122108.1 promotes lung adenocarcinoma brain metastasis and progression through the Wnt/β-catenin pathway by directly binding to aldolase A[J]. Ann Transl Med, 2021, 9(23): 1729. DOI: 10.21037/atm-21-5707.
[19]	Wang Q, Song X, Zhang Y, et al. A pro-metastatic tRNA fragment drives aldolase A oligomerization to enhance aerobic glycolysis in lung adenocarcinoma[J]. Cell Rep, 2024, 43(8): 114550. DOI: 10.1016/j.celrep.2024.114550.
[20]	石磊. 肺癌干细胞外泌体lncRNA Mir100hg影响肺癌细胞转移的机制研究[D]. 重庆: 重庆医科大学, 2024. DOI: 10.27674/d.cnki.gcyku.2024.000038.
[21]	刘子杨, 王小文, 陈力. IncRNA GK-IT1通过调控醛缩酶A影响非小细胞肺癌细胞的恶性进展[J]. 上海交通大学学报(医学版), 2022, 42(5): 591-601. DOI: 10.3969/j.issn.1674-8115.2022.05.006.
[22]	Chang YC, Chang PM, Li CH, et al. Aldolase a and phospholipase D1 synergistically resist alkylating agents and radiation in lung cancer[J]. Front Oncol, 2022, 11: 811635. DOI: 10.3389/fonc.2021.811635.
[23]	丁世凯, 张正华, 张秀莉. 降低有氧糖酵解增强非小细胞肺癌耐药细胞对顺铂的敏感性[J]. 现代肿瘤医学, 2024, 32(11): 1973-1977. DOI: 10.3969/j.issn.1672-4992.2024.11.004.
[24]	Chang YC, Yang YF, Chiou J, et al. Nonenzymatic function of aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness[J]. Cell Death Dis, 2020, 11(3): 195. DOI: 10.1038/s41419-020-2387-2.
[25]	Sobanski T, Suraweera A, Burgess JT, et al. The fructose-bisphos-phate, aldolase A (ALDOA), facilitates DNA-PKcs and ATM kinase activity to regulate DNA double-strand break repair[J]. Sci Rep, 2023, 13(1): 15171. DOI: 10.1038/s41598-023-41133-1.
[26]	Wang Z, Embaye KS, Yang Q, et al. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism‐related genes[J]. Cancer Cell Int, 2021, 21(1): 219. DOI: 10.1186/s12935-021-01915-x.
[27]	Lu G, Shi W, Zhang Y. Prognostic implications and immune infiltration analysis of ALDOA in lung adenocarcinoma[J]. Front Genet, 2021, 12: 721021. DOI: 10.3389/fgene.2021.721021.
[28]	Tian W, Zhou J, Chen M, et al. Bioinformatics analysis of the role of aldolase a in tumor prognosis and immunity[J]. Sci Rep, 2022, 12(1): 11632. DOI: 10.1038/s41598-022-15866-4.
[29]	王一喆, 金悦, 王晓楠, 等. 利用TCGA数据分析果糖二磷酸醛缩酶A对肺癌预后的预测效果[J]. 中国医科大学学报, 2020, 49(7): 586-592. DOI: 10.12007/j.issn.0258-4646.2020.07.003.

果糖二磷酸醛缩酶A在肺癌中的研究进展

Progress in the study of fructose-bisphosphate aldolase A in lung cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肺癌筛查与早诊早治方案（2024年版）[J]. 国际肿瘤学杂志, 2025, 52(4): 193-194.
[2]	文英美, 夏锦雄, 王园园, 姚颐. 放疗对抗肿瘤免疫的影响：从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236.
[3]	杨胜军, 任江, 杨丹, 龙宇, 商群献. 非小细胞肺癌组织中miR-4262、NRG1的表达水平及临床意义[J]. 国际肿瘤学杂志, 2025, 52(3): 129-135.
[4]	王逸, 王强力, 张甲, 杨懿瑾, 王盛. 结直肠癌肝转移患者组织中SUCNR1和YBX1的表达与临床病理特征及预后的关系[J]. 国际肿瘤学杂志, 2025, 52(3): 152-157.
[5]	韩涛, 贾沛沛, 鲁静. iRhom1、iRhom2、TNF-α水平对宫颈癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2025, 52(3): 158-162.
[6]	叶永英, 邹艳, 陈天明, 吴伟莉. 时钟基因Period家族在头颈鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(2): 113-118.
[7]	陈丹蕾, 邓隽军, 李淼. 循环肿瘤细胞在肺癌中的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(2): 119-123.
[8]	姬海涛, 王延峰, 刘永成, 郝楠. 基于生物信息学分析DHCR7在胃癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2025, 52(2): 94-100.
[9]	余洋, 唐仕敏, 杨露, 李娜. pT_2-3N₀M₀期胸段食管鳞状细胞癌治疗策略及预后影响因素研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 43-47.
[10]	袁胜芳, 任婕, 林卫佳, 姬泽萱, 张长洪, 王布. EGFR共突变状态对晚期肺腺癌患者预后的价值研究[J]. 国际肿瘤学杂志, 2024, 51(9): 556-562.
[11]	倪国英, 黄骞, 梁洪享, 杨志勇, 丁颖丽. 晚期非小细胞肺癌患者血清miR-499、miR-362水平变化及与预后的关系分析[J]. 国际肿瘤学杂志, 2024, 51(8): 487-492.
[12]	孟珂心, 陆海军. 口腔菌群：口腔鳞状细胞癌诊断和预后的生物标志物[J]. 国际肿瘤学杂志, 2024, 51(8): 515-519.
[13]	梁新雨, 危志刚, 叶欣. 肺部磨玻璃结节的过度诊断与过度治疗现状及对策[J]. 国际肿瘤学杂志, 2024, 51(7): 432-440.
[14]	韩艺, 张同梅, 齐菲, 张泳. 肺大细胞神经内分泌癌临床分子诊断和治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 468-473.
[15]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.